Company Overview
Surrozen, Inc. operates within the healthcare sector, specifically functioning as a biotechnology firm dedicated to discovering and developing drug candidates designed to selectively modulate the Wnt pathway for the purpose of tissue repair. The company focuses on antibody-based therapeutics that target a variety of disease areas, including conditions affecting the intestine, liver, retina, cornea, and lung. As of the latest available data, the company holds a market capitalization of $255.51M and has generated $3.48M in annual revenue over the trailing twelve months. With an employee count listed as N/A, the firm's scale is characterized by a market capitalization that suggests a mid-cap positioning within the biotechnology landscape, despite reporting revenue figures that are relatively modest in the context of large-cap pharmaceutical peers. This valuation indicates that the market is pricing the company primarily on its pipeline potential and proprietary technology rather than on current revenue generation or established market share, reflecting the typical lifecycle stage of a biotechnology entity focused on early-stage drug development.
Financial Health
The financial statements reveal a revenue figure of $3.48M for the trailing twelve months, accompanied by a net income of -$242.026M and an EBITDA of -$41.555M. The substantial gap between the positive revenue and the massive negative net income highlights an aggressive cost structure where research and development expenses or other operational costs significantly exceed the company's top-line income, a common feature in pre-revenue biotechnology firms. The company reports a free cash flow of -$16.8565M, indicating that its current operations are burning cash, which necessitates reliance on external capital sources to fund ongoing clinical trials and development activities. Margin analysis shows a gross margin of 0.0%, an operating margin of -2393.8%, and a profit margin of 0.0%, all of which signal that the company is not yet profitable and that its current business model relies entirely on future product approvals to achieve positive margins. The balance sheet maintains $89.25M in cash against $6.64M in debt, while the debt-to-equity ratio is listed as N/A, suggesting a conservative leverage position where cash reserves far exceed debt obligations. Furthermore, a current ratio of 9.22 demonstrates robust short-term liquidity, providing ample coverage for immediate obligations without the need for refinancing or asset liquidation. Finally, the return on equity is listed as N/A, and the return on assets stands at -35.7%, metrics that reflect the inherent challenges of managing capital in a high-burn environment before the company generates substantial earnings.
Valuation Assessment
Valuation metrics for Surrozen, Inc. present a complex picture, with a trailing P/E ratio listed as N/A and a forward P/E of -7.33, implying that the market does not anticipate near-term earnings that would support a traditional multiple. The price-to-book ratio is recorded at -1.36, a negative figure that indicates the company's book value is negative, likely due to the heavy accumulation of accumulated deficits in retained earnings common in biotech startups. Alternative valuation measures such as the price-to-sales ratio of 73.48 and an EV/EBITDA of -5.24 suggest that the stock is priced at a significant premium relative to its current sales, driven by expectations of future commercial success rather than current profitability. In terms of trading range, the 52-week high is $29.59 and the 52-week low is $5.90, meaning the current price sits somewhere within this wide volatility band, reflecting the speculative nature of investing in the company without earnings support. The stock exhibits a beta of 0.56, which indicates that its price volatility is lower than the broader market, suggesting that the stock may be less sensitive to general market swings than one might expect for a small-cap biotechnology stock.
Growth & Income
The company's growth profile is defined by a revenue growth rate of -19.4% year-over-year, while the earnings growth rate is listed as N/A due to the company's lack of profitability. Because earnings growth cannot be calculated against a profit base, the negative revenue growth suggests a contraction in sales or a transition period where revenue recognition methods are shifting as the company pivots toward later-stage development. Regarding income distribution, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not pay dividends. Instead of distributing cash to shareholders, the company reinvests its available liquidity, specifically the $89.25M in cash, back into its drug development pipeline and operational capabilities to pursue growth objectives. The overall growth and income profile of Surrozen, Inc. is characterized by a lack of current earnings and dividend income, relying entirely on the potential future success of its Wnt pathway drug candidates to transform its financial position.